Cite

    B. Glintborg et al.. “THU0189 One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2, 061 patients with inflammatory arthritis followed in the danbio registry.” Annals of the rheumatic diseases, vol. 77, n.d., pp. 313–314. http://access.bl.uk/ark:/81055/vdc_100144728297.0x00004c